Refine by
Diabetes Care Articles & Analysis
49 news found
Our mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond "superusers" and providing "diabetes care for the rest of us." ...
Our mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond "superusers" and providing "diabetes care for the rest of us." ...
Our mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond "superusers" and providing "diabetes care for the rest of us." ...
“These results are very important, as they show clinically meaningful effects of intralymphatic Diamyd on CGM outcomes that are of great importance to patients as they reflect the day-to-day challenges of managing their diabetes despite current best standard of care,” says Johnny Ludvigsson, Professor at Linköping University, Coordinating ...
The diabetes vaccine Diamyd is uniquely well positioned to be studied for the prevention of clinical type 1 diabetes considering its strong safety profile and clinical efficacy in recent-onset type 1 diabetes”. ...
However, in some areas as low as 15% of people with diabetes get the recommended annual diabetic eye exam to test for DR and DME. “Using innovative technology like IDx-DR gives us the opportunity to diagnose diabetic eye disease with AI at the point-of-care without physician oversite in the early stages for people who may ...
Schmid brings extensive operations and business development leadership experience in diabetes and drug delivery. As Vice President of Operations and Business Development at Insulet Corporation, he was instrumental in the development, manufacturing, and commercialization of wearable smart drug delivery pumps such as the Omnipod Diabetes Management System, the ...
Longenesis announced today the preliminary results from its study on Type 1 Diabetes care in partnership with Medtronic. In less than three months, more than 85 patients participated in the research study, providing qualitative and quantitative data on the quality of life for Type 1 diabetics using insulin pumps compared to daily insulin ...
Our mission is to improve access to the highest standards of glycemic control for people with diabetes taking it beyond "superusers" and providing "diabetes care for the rest of us." ...
Vertex grant to JDRF supports efforts to improve clinical trial diversity in type 1 diabetes The Vertex Foundation grant supports the Mass General Comprehensive Sickle Cell Disease Treatment Center Additional Vertex Foundation grant to Year Up to support health care workforce training Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that ...
(Regenstrief) today announced the development of an AI method to improve care for patients with type 2 diabetes mellitus who need complex treatment. One in 10 adults worldwide have been diagnosed with type 2 diabetes, but a smaller number require multiple medications to control blood glucose levels and avoid serious complications, such as loss of ...
China has the world’s largest Diabetic and resultingly Diabetic Foot Ulcer (DFU) population. The International Diabetes Federation estimates that 10.6% of the Chinese adult population now have diabetes that equates to 141 million people. ...
Digital Diagnostics created IDx-DR, the autonomous AI diagnostic system for the detection of diabetic retinopathy (including diabetic macular edema) at the point-of-care. Only 15% of people with diabetes receive the recommended annual diabetic eye exam.[1],[2] Access to effective diagnostic services is an ...
These open wounds may be vulnerable to infection. Proper diabetes wound care could help ward off a diabetes wound infection. Patients who take corticosteroids. ...
In December 2021, Kerendia received a Grade A recommendation in the new treatment guidelines of the American Diabetes Association (ADA), “Standards of Medical Care in Diabetes 2022” for the treatment of patients with CKD and T2D who are at increased risk for cardiovascular events or CKD progression or are unable to use a ...
ByBayer AG
He is recognized as a Key Opinion Leader on the diabetic foot, lower extremity wound care, limb salvage, podiatric medicine, and surgery. ...
Ascensia Diabetes Care, a global diabetes company, announces that its partner Senseonics has received approval from the U.S. ...
The Eversense E3, including proprietary sacrificial boronic acid (SBA) technology to extend longevity to 6 months, is planned to be available to patients in the U.S. through Ascensia Diabetes Care, Senseonics’ global commercial partner, beginning in the second quarter of 2022. ...
Modular Medical, Inc., (NASDAQ:MODD) (the "Company" or "Modular Medical"), a development-stage insulin pump company focused on providing insulin delivery without complexity to increase pump adoption and reduce the burden of diabetes care for clinicians and individuals living with diabetes, announced today the pricing of its underwritten public ...
REDWOOD CITY, Calif., Jan. 25, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today responded to Medtronic's announcement of FDA approval for painful diabetic neuropathy (PDN). "PDN represents a very large potential market, and having another competitor validate this large ...